💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

GS Paper: GS3

  • International Convention for the Prevention of Pollution from Ships (MARPOL)

    The Ministry of Shipping has informed about the steps taken for prevention and control of pollution arising from ships in the sea and in the inland waterways under the MARPOL Convention.

    Aspirants must note the following things:

    1. If the convention is a subsidiary to the United Nations/IMO,

    2. Whether it is Legally binding?

    3. If India is a signatory or not …..

    MARPOL Convention

    • MARPOL is the main international convention aimed at the prevention of pollution from ships caused by operational or accidental causes.
    • The Protocol of 1978 was adopted in response to a number of tanker accidents in 1976–1977.
    • It is one of the most important international marine environmental conventions.
    • It was developed by the IMO with an objective to minimize pollution of the oceans and seas, including dumping, oil and air pollution.
    • The Convention includes regulations aimed at preventing and minimizing pollution from ships – both accidental pollution and that from routine operations – and currently includes six technical Annexes.
    • India is a signatory to MARPOL.
    • It has six annexes (I to VI) and it deals with prevention of (1) Pollution from ships by Oil, (2) Noxious liquid substances, (3) Dangerous goods in packaged form, (4) Sewage, (5) Garbage and (6) Air pollution from ships respectively.

  • Green colour band for BS-VI 4W vehicles

    The Ministry of Road Transport and Highways (MoRTH) has issued an order mandating a coloured strip to identify four-wheeled BSVI vehicle.

    Note important PM levels allowed under BS VI norms. Note how it is different from the earlier BS IV norm.

    Details of the colour band

    • MoRTH has mandated a strip of green colour of 1 cm width on top of the existing sticker carrying details of registration for BS-VI.
    • Vehicles of any fuel type will carry the green strip irrespective of their original stickers i.e. for petrol or CNG which have a light blue colour sticker and a diesel vehicle which is of orange colour.
    • These stickers will now have a green strip of 1 cm on top for BS-VI, as mandated.

    Back2Basics:  Bharat Stage Norms

    Standard Reference Date of Implementation
    Bharat Stage II Euro 2 1 April 2005
    Bharat Stage III Euro 3 1 April 2010
    Bharat Stage IV Euro 4 1 April 2017
    Bharat Stage VI Euro 6 April 2020 with a mandate (proposed)

    Minutes of BS-VI

    • Carmakers would have to put three pieces of equipment — a DPF (diesel particulate filter), an SCR (selective catalytic reduction) system, and an LNT (Lean NOx trap) — to meet stringent BS-VI norms, all at the same time.
    • This is vital to curb both PM (particulate matter) and NOx (nitrogen oxides) emissions as mandated under the BS-VI norms.

    How is BS-VI Different from BS-IV?

    • The major difference between the existing BS-IV and forthcoming BS-VI norms is the presence of sulphur in the fuel.
    • While the BS-IV fuels contain 50 parts per million (ppm) sulphur, the BS-VI grade fuel only has 10 ppm sulphur content.
    • Also, the harmful NOx (nitrogen oxides) from diesel cars can be brought down by nearly 70%.
    • In the petrol cars, they can be reduced by 25%.
    • However, when we talk about air pollution, particulate matter like PM 2.5 and PM 10 are the most harmful components and the BS-VI will bring the cancer-causing particulate matter in diesel cars by a phenomenal 80%.

  • Airborne Rescue Pod for Isolated Transportation (ARPIT)

    The Indian Air Force has developed and inducted an Airborne Rescue Pod for Isolated Transportation (ARPIT).

    This rescue pod ARPIT can be used as an example of self-sufficiency under the ambitious Atmanirbhar Abhiyan.

    What is ARPIT?

    • ARPIT is a lightweight isolation system made from aviation certified material.
    • It has a transparent and durable cast Perspex for enhanced patient visibility which is larger, higher and wider than the existing models.
    • The isolation system caters for the suitable number of air exchanges, integration of medical monitoring instruments, and ventilation to an intubated patient.
    • In addition, it generates high constant negative pressure in the isolation chamber for prevention of infection risk to aircrew, ground crew and health care workers involved in air transportation.
    • It utilizes High-Efficiency Particulate Air (HEPA) H-13 class filters and supports invasive ventilation using Transport Ventilator.

    It’s utility

    • This pod will be utilized for the evacuation of critical patients with infectious diseases including COVID-19 from high altitude area, isolated and remote places.

  • Tax Avoidance: case study on Flipkart deal

    Through this story, we will explore how investment fund companies exploit the tax agreements between the two countries. This story involves the famous case of investment by Walmart in Flipkart. So, let’s see what was involved in the case and what argument was made by the investment fund involved in the case.

    Tax avoidance

    Tax avoidance is the use of legal methods to minimize the amount of income tax owed by an individual or a business. This is generally accomplished by claiming as many deductions and credits as is allowable. It may also be achieved by prioritizing investments that have tax advantages, such as buying municipal bonds.

    First, let’s understand why Mauritius is favourite among investors?

    • Mauritius and India do have a tax treaty to start with.
    • Suppose an investment company based out of (why not based in?) Mauritius made a lot of money selling shares of an Indian company.
    • Now, Indian authorities won’t tax the gains you made via the transaction.
    • Instead, you’ll be taxed in Mauritius.
    • But since Mauritius does not tax capital gains, you get away without paying capital gain tax.
    • So you got the answer to why Mauritius.
    • Obviously, foreign corporations lapped up this opportunity until 2016 — when the government finally decided to plug the gaps.
    • They made amendments to the treaty.

    The story of Tiger Global’s investment into Flipkart

    • Tiger Global was one of the earliest investors in Flipkart.
    • They held 22% of the company until 2018 when they sold about 17% to Walmart’s Luxembourg entity FIT Holdings.
    • This transaction was valued at over INR 14,500 Cr.
    • But Tiger Global had made its investments through funds based out of Mauritius.
    • Since Tiger Global had made most of its investments during the first half of the decade (obviously before 2016).
    • So the amendment to the treaty wasn’t really applicable to them.
    • So when they made all that money selling their stake in Flipkart, they figured they wouldn’t have to pay any tax.
    • And at first sight, this argument seems legit.

    Let’s dig deeper into the case by going through 3 arguments

    • The funds were operating out of Mauritius.
    • The directors were discharging their duties in Mauritius.
    • All in all, everything was firmly placed in Mauritius.
    • But if you peel back the layers, you’ll see that these funds are ultimately owned by Tiger Global Management LLC, USA — albeit through a maze of holding companies.
    • So, the tax authorities argued that Tiger Global had in fact set up the Mauritius based entity for the sole purpose of avoiding taxes.
    • And therefore contested that they shouldn’t be exempt from paying tax on gains they made through the Flipkart Transaction.
    • Tiger Global, miffed with the taxmen, took the matter to a quasi-judicial body — The Authority for Advance Rulings (AAR).

    And the case begins.

    Let’s look into three arguments.

    1. Focus on transaction, not on the entity that involved in the transaction

    • Tiger Global investment fund counsel had the following argument to make:
    • “It must be proven that the transaction [the final sale of shares] itself was designed to avoid taxes.”
    • And proving that the structure of the entity undertaking the transaction was designed for the avoidance of income-tax should not be necessary here.
    • So, the Revenue (the Income Tax Department) had failed to discharge its burden of proof. But AAR didn’t agree with this argument.

    2. So, what’s AAR’s argument?

    • AAR said that you don’t just compute taxes by looking at the final transaction.
    • Instead, you look at the transaction as a whole —When were the shares bought? What was the purchase price? What happened in between? Who’s the primary executioner? What’s the appreciation in value? You look at everything.
    • More importantly, the “head and brains” executing the transaction resided elsewhere.
    • Tax authorities had shown rather conclusively that a certain Mr. Charles P. Coleman (operating out of a U.S based entity) was the beneficial owner of the fund.
    • And that “he” was primarily responsible for most management decisions.
    • So the AAR hit back with the following observation:

    In our opinion, it is not the holding structure only that would be relevant. The holding structure coupled with prima facie management and control of the holding structure, including the management and control of the applicants, would be relevant factors for determining the design for avoidance of tax. The applicant companies were only a “see-through entity” to avail the benefits of India-Mauritius DTAA [Double Taxation Avoidance Agreements]

    But wait… what about the past judgements?

    • Tiger Global had another weapon in its arsenal — Past judgements on the matter.
    • Specifically, a particular ruling in the case of Moody’s Analytics Inc.
    • AAR in this case conceded that capital gains accruing to a Mauritius based entity from the transfer of shares of an Indian company shouldn’t ideally be taxed.

    3. Flipkart is a Singaporean company. So, pay the taxes!

    • The AAR said that “In this particular case, gains were made by transferring shares of a Singaporean company. Not an Indian company.”
    • That’s right. Flipkart is based out of Singapore.
    • Flipkart Singapore is the strategic shareholder of Flipkart India.
    • Flipkart India is the entity that owns most of the capital assets.
    • The shares that were sold to Walmart — that’s Flipkart Singapore, not Flipkart India.
    • But the India-Mauritius tax treaty agreement is only applicable to the transfer of shares of Indian companies.

    Is Flipkart Indian?

    Consider the question “Examine the basis used by the Authority for Advance Rulings (AAR) that led it to rule in favour of tax authorities.”

    Conclusion

    AAR concluded that there was no doubt that Tiger Global had set up the Mauritius based entity to avoid paying taxes and therefore should be liable to pay what the Income Tax authorities deem fit.

    Back2Basics: Vodafone tax

    Can India tax the gains made by selling the shares of Singaporean company?

    • According to Section 9(1)(i), (popularly known as the Vodafone tax), any income accruing or arising, whether directly or indirectly (through multiple layers), inter-alia, through the transfer of a capital asset situated in India, shall be deemed to accrue or arise in India.”
    • So Indian tax laws are pretty clear about where the gains ought to be taxed.
    • But the India-Mauritius treaty doesn’t say anything about this matter.
    • That’s why the AAR ruled the way it did.

  • Fund for pharmaceutical innovators

    Pricing of the drugs in a contentious issue across the world. In some countries like the U.S. price of the drug at 100000%  of the production cost is not atypical. In India, prices are much lower. This article suggests the novel of Health Impact Fund which could strike the balance between affordability and R&D.

    Medicines: Humanities greatest achievements

    • They have helped attain dramatic improvements in health and longevity as well as huge cost savings through reduced sick days and hospitalizations.
    • The global market for pharmaceuticals is currently worth ₹110 lakh crore annually, 1.7% of the gross world product (IPFPA 2017, 5).
    • Roughly 55% of this global pharmaceutical spending, ₹60 lakh crore, is for brand-name products, which are typically under patent.

    Issue of high drug prices

    • Commercial pharmaceutical research and development (R&D) efforts are encouraged and rewarded through the earnings that innovators derive from sales of their branded products.
    • These earnings largely depend on the 20-year product patents they are entitled to obtain in WTO member states.
    • Such patents give them a temporary monopoly, enabling them to sell their new products without competition at a price far above manufacture and distribution costs, while still maintaining a substantial sales volume.
    • In the United States, thousandfold (100000%) markups over production costs are not atypical.
    • In India, the profit-maximising monopoly price of a new medicine is much lower, but similarly unaffordable for most citizens.

    Covering large R&D costs: before we think about a solution

    • To be sure, before such huge markups can yield any profits, commercial pharmaceutical innovators must first cover their large R&D costs.
    • Currently, this cost is  ₹14 lakh crore a year (Mikulic 2020).
    • This includes the cost of clinical trials needed to demonstrate safety and efficacy, the cost of capital tied up during the long development process, and the cost of any research efforts that failed somewhere along the way.

    Three concerns with R&D

    1. Neglect of the diseases suffered by the poor

    • Innovators motivated by the prospect of large markups tend to neglect diseases suffered mainly by poor people, who cannot afford expensive medicines.
    • The 20 WHO-listed neglected tropical diseases together afflict over one billion people (WHO n.d.) but attract only 0.35% of the pharmaceutical industry’s R&D (IFPMA 2017, 15 and 21).
    • Merely 0.12% of this R&D spending is devoted to tuberculosis and malaria, which kill 1.7 million people each year.

    2. High prices of new medicines

    • Thanks to a large number of affluent or well-insured patients, the profit-maximising price of a new medicine tends to be quite high.
    • Consequently, most people around the world cannot afford advanced medicines that are still under patent.
    • This is especially vexing because manufacturing costs are generally quite low.

    3. Rewards are poorly correlated to the therapeutic value of drugs

    • Firms earn billions by developing duplicative drugs that add little to our pharmaceutical toolbox — and billions more by cleverly marketing their drugs for patients who won’t benefit.
    • These large R&D investments would be much better spent on developing new life-saving treatments for deadly diseases plaguing the world’s poor.

    Health Impact Fund: Solution to the above problems

    • The Health Impact Fund as an alternative track on which pharmaceutical innovators may choose to be rewarded.
    • The basic idea behind it:
    • Any new medicine registered with the Health Impact Fund would have to be sold at or below the variable cost of manufacture and distribution.
    • But would earn ten annual reward payments based on the health gains achieved with it.

    How health impact fund would work?

    • The Health Impact Fund could start with as little as ₹20000 crore per annum and might then attract some 10-12 medicines, with one entering and one exiting in a typical year.
    • Registered products would then earn some ₹17000-₹20000 crore, on average, during their first ten years.
    • Of course, some would earn more than others – by having greater therapeutic value or by benefiting more people.
    • Long-term funding for the Health Impact Fund might come from willing governments.
    • Those countries would contribute in proportion to their gross national incomes — or from an international tax, perhaps on greenhouse gas emissions or speculative financial transactions.
    • Non-contributing affluent countries would forgo the benefits: the pricing constraint on registered products would not apply to them.
    • This gives innovators more reason to register as they can still sell their product at high prices in some affluent countries and affluent countries reason to join.

    The fund will have the following 5 major benefits

    1. Help the Neglected areas of research

    • The Health Impact Fund would get pharmaceutical firms interested in certain R&D projects that are unprofitable under the current regime – especially ones expected to produce large health gains among mostly poor people.
    • With the Health Impact Fund in place, there can be more research on diseases like Tuberculosis or Malaria, even Covid.
    • We can develop rich arsenal of effective interventions and greater capacities for targeted responses quickly.

    2. Rewarding health outcomes and not sales

    • The Health Impact Fund will focus on performance of drugs and not make it a marketing stunt.
    • Like in its model, firms would earn annual reward payments based on the health gains achieved with by the medicine.
    • Present scenario: firms seek to influence hospitals, insurers, doctors and patients to use their patented drug and to favour it over other more effective medicines.

    3. Sustainable research and marketing system

    • A reward mechanism oriented towards health gains rather than high-markup sales would lead to a sustainable research-and-marketing system.
    • How? Simple for health gains, innovators will have to ensure:
    • They will have to think holistically about how their drug can work in the context of many other factors relevant to treatment outcomes.
    • They will need to think about therapies and diagnostics together, in order to identify and reach the patients who can benefit most.
    • They will need to monitor results in real time to recognize and address possible impediments to therapeutic success.
    • Finally, they will have need to ensure that patients have affordable access to the drug and are properly instructed and motivated to make optimal use of it with the drug still in prime condition.
    • Such a system would obviously make research more streamlined and sustainable.

    4. No fear of compulsory licence clause

    • Participation of commercial pharmaceutical firms is crucial for tackling global pandemics.
    • At present such firms have issues with use of compulsory licences by governments as it divest them of their monopoly rewards.
    • Health Impact Fund registration would remove this risk as states would have no reason to interfere with innovators whose profit lies in giving real and rapid at-cost access to their new product to all who may need it.

    5. Holistic approach

    • Multinational firms can collaborate with national health systems, international agencies and NGOs, to build a strong public-health strategy around its product.
    • The highest goal here would be complete eradication of many communicable diseases(Example: Malaria) which we are fighting right now.

    Can we apply the above to Covid-19?

    • Applying it to a new disease like COVID-19 is complicated by the fact that we lack here a well-established baseline representing the harm the disease would have done in the absence of the new medicine to be assessed.
    • For malaria, such a baseline can be established on the basis of a stable disease trajectory observable over many years.
    • In the case of a new epidemic, one must rely on a modelling exercise that estimates the baseline trajectory on the basis of obtainable data about the spread of the disease and its impact on infected patients.
    • This surely is a challenging undertaking which cannot yield precise or uncontroversial results about what damage the epidemic would truly have done if the vaccine or medication in question had not appeared.

    Consider the question “Drug pricing has always plagued the authorities and policymakers. Cap it and you tend to lose on innovation. Deregulate it, and high prices make it unaffordable. In light of this, examine the issues with the R&D in the pharmaceutical sector and suggest the ways to strike the balance between lives and innovation.”

     Conclusion

    The Health Impact Fund would give innovators the right incentives. It would guide them to ask not: how can we develop an effective product and then achieve high sales at high markups? But rather: how can we develop an effective product and then deploy it so as to help reduce the overall disease burden as effectively as possible?

  • Explained: Gross Value Added (GVA) Method

    The National Statistical Office (NSO) recently released its provisional estimates of national income for the financial year 2019-20. The release also detailed the estimates of the Gross Value Added (GVA).

    Try this question from CSP 2011:

    Q. In the context of Indian economy, consider the following statements

    1. The growth rate of GDP has steadily increased in the last five years.

    2. The growth rate in per capita income has steadily increased in the last five years.

    Which of the statements given above is/are correct?

    (a.) 1 only

    (b.) 2 only

    (c.) Both 1 and 2

    (d.) Neither 1 nor 2

    The GVA method

    • In 2015, in the wake of a comprehensive review of its approach to GDP measurement, India opted to make major changes to its compilation of national accounts.
    • It aims to bring the whole process into conformity with the UN System of National Accounts (SNA) of 2008.

    What is GVA?

    • As per the SNA, GVA is defined as the value of output minus the value of intermediate consumption.
    • GVA is a measure of the contribution to GDP made by an individual producer, industry or sector.
    • At its simplest, it gives the rupee value of goods and services produced in the economy after deducting the cost of inputs and raw materials used.
    • It can be described as the main entry on the income side of the nation’s accounting balance sheet, and from economics, perspective represents the supply side.

    How it has changed income calculation?

    • While India had been measuring GVA earlier, it had done so using ‘factor cost’.
    • GDP at ‘factor cost’ was the main parameter for measuring the country’s overall economic output until the new methodology was adopted.
    • GVA at basic prices became the primary measure of output across the economy’s various sectors and when added to net taxes on products amounts to the GDP.
    • In the new series, the base year was shifted to 2011-12 from the earlier 2004-05.

    GVA estimates by NSO

    • As part of the data on GVA, the NSO provides both quarterly and annual estimates of output — measured by the gross value added — by economic activity.
    • The sectoral classification provides data on eight broad categories that span the gamut of goods produced and services provided in the economy.
    • These are: 1) Agriculture, Forestry and Fishing; 2) Mining and Quarrying; 3) Manufacturing; 4) Electricity, Gas, Water Supply and other Utility Services; 5) Construction; 6) Trade, Hotels, Transport, Communication and Services related to Broadcasting; 7) Financial, Real Estate and Professional Services; 8) Public Administration, Defence and other Services.

    How relevant is the GVA data given that headline growth always refers to GDP?

    • The GVA data is crucial to understand how the various sectors of the real economy are performing.
    • The output or domestic product is essentially a measure of GVA combined with net taxes.
    • However, GDP can be and is also computed as the sum total of the various expenditures incurred in the economy.
    • It includes private consumption spending, government consumption spending and gross fixed capital formation or investment spending; these reflect essentially on the demand conditions in the economy.

    Significance of GVA

    • From a policymaker’s perspective, it is vital to have the GVA data to be able to make policy interventions, where needed.
    • Also, from global data standards and uniformity perspective, GVA is an integral and necessary parameter in measuring a nation’s economic performance.

    Issues with GVA

    • As with all economic statistics, the accuracy of GVA as a measure of overall national output is heavily dependent on the sourcing of data and the fidelity of the various data sources.
    • To that extent, GVA is as susceptible to vulnerabilities from the use of inappropriate or flawed methodologies as any other measure.
    • Economists argue that India’s switch of its base year to 2011-12 had led to a significant overestimation of growth.
    • They argued that the value-based approach instead of the earlier volume-based tack in GVA estimation had affected the measurement of the formal manufacturing sector and thus distorted the outcome.

  • Getting closer to doubling income of Farmers

    agriculture plays an important role in decreasing rural poverty in developing countries. Improved irrigation methods, seeds, and fertilizers have led to increased agricultural production in rural areas. The ECA is an act which was established to ensure the delivery of certain commodities or products, the supply of which if obstructed owing to hoarding or black-marketing would affect the normal life of the people. The ECA was enacted in 1955. This includes foodstuff, drugs, fuel (petroleum products) etc

  • Rare-earth based Magnetocaloric materials for cancer treatment

    Indian scientists have developed a rare-earth-based magnetocaloric material that can be effectively used for cancer treatment.

    Magnetocaloric Effect does have other applications like in the field of medical implants but for use in energy field, it is still in nascent stage.

    From exam perspective, do understand what principles lies behind this effect.

    What is Magnetocaloric Effect?

    • Magnetocaloric effect (MCE) is a phenomenon where the application and removal of a magnetic field cause certain materials to get warmer and cooler, respectively.
    • This effect normally occurs near its Curie temperature where the application of the field makes the material to warm up and cools up when the field is removed.

    Issue of hyperthermia in cancer treatment

    • Advancements in magnetic materials led to the development of magnetic hyperthermia to try to address the issues of side effects of cancer treatment like chemotherapy.
    • In magnetic hyperthermia, magnetic nanoparticles are subjected to alternating magnetic fields of few Gauss, which produce heat due to magnetic relaxation losses.
    • Usually, the temperature required to kill the tumour cells is between 40 and 45°C.
    • However, the drawback in magnetic hyperthermia is the lack of control of temperature, which may damage the healthy cells in the body and also have side effects like increased BP, hair losses etc.

    Here comes in, Magnetocaloric materials

    • This hypothermia can be avoided by using magnetocaloric materials, as it can provide controlled heating.
    • The advantage of magnetocaloric materials which heat up or cool down with the application and removal of the magnetic field, respectively is that as soon as the magnetic field is removed, the cooling effect is generated.
    • The team at ARCI chose rare-earth-based alloy for studies as some of the rare earth materials are human body compatible.
    • The heating capacity would increase with the increase in the magnetic field.

  • “Healthy and Energy Efficient Buildings” Initiative

    The Energy Efficiency Services Limited (EESL) has launched the “Healthy and Energy Efficient Buildings” initiative that will pioneer ways to make workplaces healthier and greener.

    Possible prelims question:

    Q. The MAITREE programme recently seen in news is related to: Trade/Energy Efficiency/Climate Change/ Strategic Relations

    About the Initiative

    • The initiative has been launched by EESL in partnership with the U.S. Agency for International Development’s (USAID) MAITREE program.
    • As part of this initiative, EESL has taken the leadership by being the first to implement this framework in its own offices.
    • This initiative addresses the challenges of retrofitting existing buildings and air conditioning systems so that they are both healthy and energy-efficient.
    • It will pave the way for other buildings to take appropriate steps to be healthy and energy-efficient.

    What is the MAITREE program,?

    • The Market Integration and Transformation Program for Energy Efficiency (MAITREE) is a part of the US-India bilateral Partnership between the Ministry of Power and USAID.
    • It is aimed at accelerating the adoption of cost-effective energy efficiency as a standard practice within buildings and specifically focuses on cooling.

    Significance of the initiative

    • Poor air quality has been a concern in India for quite some time and has become more important in light of the COVID pandemic.
    • As people return to their offices and public spaces, maintaining good indoor air quality is essential for occupant comfort, well-being, productivity and the overall public health.
    • Most buildings in India are not equipped to establish and maintain healthy indoor air quality and need to be upgraded.
    • The EESL office pilot will address this problem by developing specifications for future use in other buildings throughout the country.
    • It will aid in evaluating the effectiveness and cost benefits of various technologies and their short and long-term impacts on air quality, comfort, and energy use.

     Back2Basics: EESL

    • Energy Efficiency Services Limited (EESL), under the administration of Ministry of Power, is working towards mainstreaming energy efficiency.
    • It is implementing the world’s largest energy efficiency portfolio in the country.
    • EESL aims to create market access for efficient and future-ready transformative solutions that create a win-win situation for every stakeholder.
    • About USAID: USAID is the world’s premier international development agency and a catalytic actor driving development results.

  • Serotonin Hormone causes Locust to form Swarms

    Scientists have attempted to answer an important scientific question of how and why locusts collect together by the thousands in order to make a swarm.

    Quite often, Oxytocin hormone is seen in the news for its commercial uses and associated ethical concerns. Kindly go through Oxytocin and issues over its commercial use

    What causes Locusts to form huge swarms?

    • When lone locusts happen to come near each other (looking for food) and happen to touch each other, this tactile stimulation, even just in a little area of the back limbs, causes their behaviour to change.
    • This mechanical stimulation affects a couple of nerves in the animal’s body, their behaviour changes, leading to their coming together.
    • The central nervous system of the locust, the most important among them being serotonin which regulates mood and social behaviour is the mystery behind swarms.
    • Their coming together triggers a mechanical (touch) and neurochemical (serotonin) stimulations to make crowding occur.

    What is Serotonin?

    • It is a monoamine neurotransmitter.
    • It has a popular image as a contributor to feelings of well-being and happiness.
    • Its actual biological function is complex and multifaceted, modulating cognition, reward, learning, memory, and numerous physiological processes such as vomiting and vasoconstriction.